From Name:
From Email:
To Name:
To Email:

Optional Message:

Mediwound announces positive top-line results from its study for eschar removal of severe thermal burns

from The Associated Press

MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has met its primary and all secondary endpoints in its pivotal U.S. Phase 3 clinical study (DETECT) with NexoBrid to treat patients with deep partial thickness (DPT) and full thickness (FT) thermal burns intended for submission for Biological License Application (BLA) from U.S. Food and Drug Administration (FDA). more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063